Meeting
2018 ASCO Annual Meeting
Immunologic and clinical implications of CD73 expression in non-small cell lung cancer (NSCLC).
Authors
Lee Chun Park
Northwestern University Feinberg School of Medicine, Chicago, IL
Lee Chun Park , Kyunghoon Rhee , Won Bin Kim , Anderson Cho , Junho Song , Jonathan Forrest Anker , Michael Oh , Preeti Bais , Sandeep Namburi , Jeffrey Chuang , Young Kwang Chae
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Immunobiology
Citation
J Clin Oncol 36, 2018 (suppl; abstr 12050)
DOI
10.1200/JCO.2018.36.15_suppl.12050
Abstract #
12050
Poster Bd #
163
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
First Author: Diane Damotte
Poster
2023 ASCO Annual Meeting
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
First Author: Yuming Zhu
Poster
2022 ASCO Annual Meeting
PD-L1 score as a prognostic biomarker in Asian patients with early-stage, EGFR-mutated lung cancer.
First Author: Stephanie Saw
Poster
2024 ASCO Annual Meeting
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.
First Author: Melissa Lynne Johnson